HC News

• EMA approval for new drug to treat Alzheimer’s disease
• El papel del radiofísico hospitalario
• Katia Vandekerckhove, dietista- nutricionista especializada en SIBO, microbiota y metagenómica
• A clear and stable vision with cataract surgery at HC Marbella
• Ageing is a luxury, let’s not forget it
• Vårdgarantier för våra nordiska patienter
• Tomas Arrazola. Farmacéutico hospitalario superespecializado en oncología
• Advances and challenges in the fight against cancer
• HC Marbella recibe la certificación ISO 9001:2015, reafirmando su compromiso con la calidad y seguridad asistencial
• Alcohol consumption among adolescents
• More news

Update in prostate cancer: benefits of prostate specific antigen (PSA) and its screening

What are the benefits of PSA?

It is shown that PSA screening reduces deaths from prostate cancer.

 

At what age should I do it?

If there is a family history we recommend from the 40, otherwise it is recommended after 45-50 years.

The age that we do not recommend PSA is not defined, but for very elderly patients with associated major illness this does not seem to bring benefits.

 

Are there new biomarkers of prostate cancer alternative to PSA?

They are currently developing new markers for the detection of prostate cancer. For now, the PSA and its molecular formulas remain the reference, although new markers appear promising.

Example of bookmarks to decide when biopsy: pro-PSA, kallikrein K4, PCA3 gene.

There are also monograms or models to calculate the risk of prostate cancer; they can assist decision-making between the doctor and the patient, and to agree with the patient with the risks and benefits of PSA screening.

 
 
Dr. José Manuel Fernández Montero
Director of the Urology Unit of HC Marbella
 
 

June 11th World Day of Prostate Cancer

www.cancerprostata.org

 

 

 

 

June 11, 2015

 

 

 

Read other news